Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001600620-24-000112
Filing Date
2024-11-12
Accepted
2024-11-12 19:05:46
Documents
1
Period of Report
2024-11-07

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1731456339.html 3  
1 FORM 3 wk-form3_1731456339.xml 3 3773
  Complete submission text file 0001600620-24-000112.txt   5148
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Issuer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address #140-14315 118 AVE NW EDMONTON A0 T5L 4S6
Business Address
Keenan Greg (Reporting) CIK: 0002044006 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36421 | Film No.: 241450584